Hixon Zuercher LLC Cuts Stock Holdings in Stryker Co. (NYSE:SYK)

Hixon Zuercher LLC cut its stake in Stryker Co. (NYSE:SYK) by 0.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,091 shares of the medical technology company’s stock after selling 156 shares during the period. Stryker makes up 3.1% of Hixon Zuercher LLC’s holdings, making the stock its 6th largest position. Hixon Zuercher LLC’s holdings in Stryker were worth $7,981,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in SYK. Norden Group LLC acquired a new stake in shares of Stryker in the first quarter valued at approximately $280,000. Central Pacific Bank Trust Division acquired a new stake in Stryker in the 1st quarter valued at about $39,000. Cohen Capital Management Inc. lifted its position in shares of Stryker by 0.3% in the first quarter. Cohen Capital Management Inc. now owns 85,108 shares of the medical technology company’s stock valued at $30,458,000 after buying an additional 261 shares during the last quarter. TFG Advisers LLC boosted its stake in shares of Stryker by 0.8% during the 1st quarter. TFG Advisers LLC now owns 13,614 shares of the medical technology company’s stock worth $4,872,000 after acquiring an additional 102 shares during the period. Finally, Manchester Capital Management LLC increased its holdings in shares of Stryker by 1.4% during the 1st quarter. Manchester Capital Management LLC now owns 2,474 shares of the medical technology company’s stock worth $885,000 after acquiring an additional 34 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the subject of several research analyst reports. Citigroup lifted their target price on shares of Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, October 1st. BTIG Research boosted their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Wolfe Research initiated coverage on Stryker in a research note on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price target on the stock. Finally, Morgan Stanley boosted their price target on Stryker from $345.00 to $350.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $393.65.

Stryker Price Performance

Stryker stock opened at $369.86 on Wednesday. The stock’s 50 day moving average is $360.66 and its 200 day moving average is $344.95. Stryker Co. has a one year low of $266.93 and a one year high of $374.63. The firm has a market cap of $141.00 billion, a P/E ratio of 39.64, a P/E/G ratio of 2.77 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.46 earnings per share. As a group, research analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Insider Activity

In related news, insider Viju Menon sold 600 shares of Stryker stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, insider Viju Menon sold 600 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now directly owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of the firm’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00. Following the transaction, the vice president now directly owns 10,042 shares in the company, valued at $3,715,540. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,068 shares of company stock worth $3,693,972. Company insiders own 5.50% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.